Athens

• A clinical study of pembrolizumab and other treatments for non-small cell lung cancer (MK-3475-01G) Ended recruitment
  2024-515772-12-00 4 2025-04-18 Lung neoplasm malignant (Stage IV Non-small cell lung cancer)
• A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended recruitment
  2024-516609-22-00 5 2025-04-15 Primary Sjögren’s Disease
• A study to learn if a combination of Fianlimab and Cemiplimab versus Cemiplimab alone is more effective for adult participants with Advanced … Ended recruitment
  2022-501483-18-00 10 2025-03-28 Advanced Non-Small Cell Lung Cancer
• BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part … Ended recruitment
  2024-515740-23-00 5 2025-03-25 Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active … Ended recruitment
  2024-516213-20-00 5 2025-03-25 Psoriatic arthritis
• A study to assess efficacy and safety of efgartigimod PH20 SC in adults with ocular myasthenia gravis Ended recruitment
  2024-514133-38-00 5 2025-03-19 Ocular Myasthenia Gravis
• EMAPALUMAB TREATMENT FOR ANTICIPATED CLINICAL BENEFIT IN SEPSIS DRIVEN BY THE INTERFERON-GAMMA ENDOTYPE (THE EMBRACE TRIAL) Ended recruitment
  2024-515255-38-00 4 2025-03-12 SEPSIS
• A study to investigate improvement in pruritus of Lichen Simplex Chronicus with dupilumab injections compared with placebo in male and fema … Ended recruitment
  2024-514762-39-00 5 2025-03-03 Neurodermatitis
• AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protoco … Ended recruitment
  2024-511253-21-00 3 2025-02-28 Thoracic tumors with homozygous MTAP-deletion
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended recruitment
  2024-512998-27-00 5 2025-02-21 Non-Small Cell Lung Cancer
• STEP TEENS Weight Maintenance: A research study on how well semaglutide helps teenagers with excess body weight to lose weight and maintain … Ended recruitment
  2023-508055-40-00 6 2025-02-18 Obesity
• A Study to Learn About the Investigational Medicine Called PF-06821497 (mevrometostat) in Men with mCRPC Who Were Previously Treated with Ab … Ended recruitment
  2024-511650-50-00 5 2025-01-17 METASTATIC CASTRATION RESISTANT PROSTATE CANCER
• Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemother … Ended recruitment
  2024-511957-23-00 5 2025-01-03 Recurrent or Persistent Endometrial Cancer
• A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab … Ended recruitment
  2024-511933-36-00 4 2025-01-02 Diffuse cutaneous systemic sclerosis (dcSSc)
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513208-32-00 5 2024-12-16 Chronic Spontaneous Urticaria
• A trial to evaluate efficacy and safety of buloxibutid in people with idiopathic pulmonary fibrosis Ended recruitment
  2023-509069-19-00 4 2024-12-12 idiopathic pulmonary fibrosis
• Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended recruitment
  2024-510730-40-00 5 2024-12-12 Hidradenitis Suppurativa
• Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended recruitment
  2023-504359-29-01 5 2024-12-11 Multiple sclerosis
• An open-label study to collect safety and effectiveness information on long-term treatment with vamorolone in boys with Duchenne Muscular Dy … Ended recruitment
  2024-512828-12-00 6 2024-12-05 Duchenne Muscular Dystrophy
• Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph … Ended recruitment
  2023-505989-29-00 5 2024-11-21 Extensive stage small cell lung cancer (ES-SCLC)
• A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination with Intravenously … Ended recruitment
  2024-512147-23-00 10 2024-11-21 Chronic Lymphocytic Leukemia
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended recruitment
  2024-514343-29-00 5 2024-11-19 multiple sclerosis
• Apremilast study in children with active oral ulcers associated with Behçet's Disease Ended recruitment
  2023-503436-40-00 5 2024-11-11 Behcet's disease
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis Ended recruitment
  2024-510753-10-00 5 2024-11-01 Prurigo Nodularis

Showing 433–456 of 905 trials